CSF2 and melanoma: GM-CSF stimulates the differentiation, activation, and migration of DCs (139, 140), and consistently, administration of the CpG ODN/GM-CSF combination in melanoma patients results in enhanced mutation of all identifiable DC subpopulations and the recruitment of T-cell-stimulating and cross-presenting DCs to support protective melanoma immunity (141).